Analysis of a common diabetes drug's randomized trial during active surveillance for low-risk prostate cancer and implications for targeted intervention.
Key Takeaways
- MAST, a randomized trial, found no overall delay in cancer progression with metformin
- Obese men on metformin showed higher pathologic progression versus placebo, hazard ratio 2.36
- Prior large trial also failed to improve overall survival when metformin was added